pimecrolimus topical / Generic mfg. - LARVOL DELTA

Calcineurin Inhibitors: Current Role, Toxicity Management, and Future Frontiers in Immunosuppression. (PubMed, Mol Neurobiol) - "Cyclosporine, tacrolimus, pimecrolimus and newer derivatives of cyclosporine such as voclosporin are calcineurin inhibitors (CNIs), have a potent immunosuppressant effect...This necessitates the need of continuous monitoring of drug concentrations and management of cardiovascular and metabolic risk factors. This narrative review summarizes the mechanism(s), the current clinical application(s), the safety concern(s), and the future direction(s) of the safer and targeted use of CNIs."

Adverse events • Journal • Review • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Transplantation • IL2 • NFATC1

Engineering of FK520 polyketide synthase for rapid access to quality control reference standards. (PubMed, Microb Cell Fact) - "The immunosuppressants FK506, FK520, and its chlorinated derivate pimecrolimus, are well known for accumulation of minor congeners in the fermentation, which demands costly and lengthy purification with industrial HPLC to obtain material of sufficient purity...It appears that the selectivity of the downstream AT4-containing module depends on the structural features of the incoming acyl chain; features installed by a module well upstream in the assembly line. Therefore, the global context of the PKS may be more impactful to the outcome of AT-engineering experiments than is generally considered."

Journal

The effects of Chinese botanical lotion and pimecrolimus cream in the treatment of chronic perianal eczema: a randomized clinical trial. (PubMed, Front Pharmacol) - "The combination of pimecrolimus cream and APL is more effective in the treatment of CPE than pimecrolimus cream alone, providing a promising new approach for the clinical management of perianal eczema. International Traditional Medicine Clinical Trial Registry, http://itmctr.ccebtcm.org.cn/en-US/Home/ProjectView?pid=58f1a168-bdf1-4e2a-a9bd-cf0f4a3ec06f as ITMCTR 2024000576."

Clinical • Journal • Atopic Dermatitis • Dermatology • Immunology • Pruritus

Temporarily induced facial eczema by IL-17 inhibitors: a case report and literature review. (PubMed, Front Allergy) - "After oral compound glycyrrhizin, olopatadine hydrochloride, triprolidine hydrochloride, and topical pimecrolimus for a week, his facial lesions were completely cleared. No recurrence of similar rash or other adverse effects was observed during the subsequent follow-up period over 5 months. It is concluded that eczema could be induced temporarily by secukinumab, and maybe continued application."

Journal • Alopecia • Atopic Dermatitis • Dermatology • Immunology • Psoriasis • Pyoderma Gangrenosum • Sarcoidosis • IL17A

VULIS-3T: Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy. (clinicaltrials.gov) - P=N/A | N=45 | Not yet recruiting | Sponsor: Milosz Pietrus

New trial • Dermatology

Rebound New Atopic Dermatitis in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors (ACG 2025) - "All patients were treated with either topical steroids or pimecrolimus and an oral antihistamine for newly diagnosed AD... The mean age of the patients was 36.9 years (SD 9.2), with a median disease duration of 15 years (IQR 12-23). The median time from JAKi withdrawal to AD onset was 7 days (IQR 2-12). The rash was often described as pruritic and erythematous papules that were located on the face, anterior and posterior trunk, and upper extremities."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Rheumatology

Acquired Speckled Acrofacial Hypomelanosis: A Novel Case Report. (PubMed, Case Rep Dermatol) - "This case represents a novel presentation of acquired speckled acrofacial hypomelanosis with unique findings, including facial involvement and absence of hyperpigmentation. The patient's excellent response to pimecrolimus cream suggests this may be an effective treatment option for this rare condition."

Journal • Dermatology • Pediatrics

Upadacitinib Induced Facial Erythema and Edema in Atopic Dermatitis: A Paradoxical Adverse Event (EADV 2025) - "Materials & A 29-year-old female with long-standing moderate-to-severe AD was started on upadacitinib 15 mg/day following insufficient response and accessibility to prior treatments (topical agents, cyclosporine, phototherapy, baricitinib)...Upadacitinib was discontinued and pimecrolimus cream was initiated; subsequent clinical evaluation revealed partial regression of facial erythema following drug discontinuation... Facial dermatitis is a well-documented adverse event during dupilumab therapy, potentially linked to Malassezia hypersensitivity, rosacea, or allergic contact dermatitis. While JAK inhibitors are typically used to manage such cases, we report a rare paradoxical reaction where facial dermatitis was induced by JAK inhibition with upadacitinib. The exact mechanism remains unclear, but one plausible explanation involves the disinhibition of Th1 and Th17 pathways secondary to the suppression of Th2 cytokines such as IL-4 and IL-13."

Adverse events • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Pruritus • Rosacea • IL13 • IL17A • IL22 • IL4 • JAK1

German AD-Best TREAT Registry (EADV 2025) - "The most commonly prescribed systemic therapy was Dupixent (n=77), followed by Lebrikizumab (n=26), Tralokinumab (n=22), Abrocitinib (n=13), Upadacitinib (n=10), Baricitinib (n=3), and others (n=2). In total, 66,86% (n=117) of patients received topical treatment, with 45,71% (n=80) treated with tacrolimus, 38,86% (n=68) with pimecrolimus, and 12,57% (n=22) with topical steroids. ADBest-TREAT provides an efficient platform for large-scale data collection, offering valuable insights into the real-world management of AD in Germany. With the anticipated inclusion of additional centers in the coming years, its capacity to generate comprehensive real-world evidence is expected to further expand."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Topical Calcineurin Inhibitors versus Topical Antifungals for the Treatment of Seborrheic Dermatitis: A Systematic Review and Meta-Analysis (EADV 2025) - "A total of 282 patients were included for this analysis, 140 received 1% Pimecrolimus or 0.03% to 0.1% Tacrolimus were compared with 142 patients that underwent antifungal therapies, such as 2% Ketoconazole/Sertaconazole or 1% Ciclopirox Olamine. This meta-analysis investigated the effectiveness of topical calcineurin inhibitors compared to topical antifungals in reducing clinical severity scores (Scoring Index – SI) in patients with seborrheic dermatitis. Based on our results, no statistically significant difference was observed between the two treatments, suggesting similar clinical efficacy. These findings underscore the need for further large-scale, high-quality studies to confirm and expand upon these results."

Retrospective data • Review • Dermatitis • Dermatology • Immunology • Seborrheic Dermatitis

Early Intervention with Topical Calcineurin Inhibitors in Pediatric Segmental Vitiligo: a Case Series Challenging Prognostic Expectations (EADV 2025) - "Materials & Four pediatric patients (ages 8–11) with early-onset SV were treated with tCNIs twice daily, either topical tacrolimus 0.1% ointment or pimecrolimus 1% cream. Topical calcineurin inhibitors can be an effective and well-tolerated option for treating pediatric SV, especially when initiated early. Our findings suggest that early immune modulation may preserve melanocytes and improve outcomes, even in cases with traditionally poor prognostic indicators such as leukotrichia. However, further studies are warranted to confirm these findings and establish standardized treatment protocols."

Clinical • Dermatology • Immune Modulation • Immunology • Pediatrics • Vitiligo

Jessner-Kanof Lymphocytic Infiltration: Case Report and Review of a Rare Cutaneous Entity (EADV 2025) - "Treatment was initiated with systemic prednisone at a dose of 75 mg/day with a tapering regimen, alongside topical pimecrolimus. Jessner-Kanof lymphocytic infiltration is a rare cutaneous disorder that may clinically and histologically mimic other inflammatory dermatoses, particularly cutaneous lupus erythematosus. Recognition of its distinctive features and the use of histopathological correlation are critical for an accurate diagnosis. This case highlights the importance of including JKLI in the differential diagnosis of chronic erythematous plaques, especially in patients with negative autoimmune serology."

Case report • Clinical • Review • Cognitive Disorders • Cutaneous Lupus Erythematosus • Dermatology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus

Familial Lichen Planus with Different Distribution Patterns In a Family From Pakistan (EADV 2025) - "The mother was treated with topical 1% pimecrolimus cream, showing a good response, although marked post-inflammatory hyperpigmentation persisted... Familial LP is a rare entity, with an incidence ranging from 1% to 11% of all LP cases. These cases tend to present at earlier ages and often with atypical, chronic, and severe patterns. A classical association has been reported between familial LP and certain HLA types, including HLA-B7, HLA-DR1, and HLA-DR4."

Dermatitis • Dermatology • Dermatopathology • Immunology • Inflammation • Lichen Planus

Case report: Therapeutic Challenges of adult-onset refractory Discoid Lupus Erythematosus with comorbid rosacea (EADV 2025) - "The treatment course is gradual: originally treated with topical corticosteroids, if unresponsive, hydroxychloroquine is introduced, followed by immunosuppressants in refractory cases...Following diagnosis, the patient alternated between topical treatments, including the calcineurin inhibitors tacrolimus and pimecrolimus, as well as clobetasol, with no significant clinical improvement...Combined treatment with doxycycline 40mg/day and prednisolone 40 mg/day was initiated with limited response. Then, treatment with methotrexate 10 mg/week and topical Ivermectin was initiated, resulting in the gradual remission of DLE... This case urges the importance of recognising treatment-resistant DLE due to comorbid granulomatous rosacea and demodicosis: the disease can present with refractory behaviour and not respond to immunomodulators and topical corticosteroids. The case highlights how coexisting rosacea exacerbates and prolongs DLE symptoms, emphasizing the need for a..."

Case report • Clinical • Dermatitis • Dermatology • Dermatopathology • Discoid Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Rosacea

Calcineurin inhibitors compared to corticosteroids for atopic dermatitis treatment in children: a systematic review and meta-analysis (EADV 2025) - "Materials & We searched the PubMed, Embase, and Cochrane databases up to December 2024 for studies comparing topical calcineurin inhibitors (TCIs) such as pimecrolimus, tacrolimus, or cyclosporine with topical corticosteroids (TCS) in children and adolescents with atopic dermatitis (AD)... In our analysis, TCIs demonstrated similar effectiveness to TCS in children with atopic dermatitis (AD). For patients unable to use TCS, TCIs can serve as a suitable alternative in the search for steroid-sparing or alternative therapies. However, it is important to consider the higher risk of side effects when weighing the benefits and risks of these two."

Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

A Novel Topical JAK1 Inhibitor for Atopic Dermatitis: Safety and Early Efficacy of IN-115314 (EADV 2025) - "In the patient cohort, individuals with 3–30% body surface area (BSA) involvement and mild to moderate AD (EASI score < 23) received either 1% or 3% IN-115314 ointment, or pimecrolimus cream, applied twice daily for 28 days, with twelve participants (8 active:4 comparator) in each group. IN-115314 showed favorable safety, low systemic exposure, and early signs of clinical efficacy when applied topically to both healthy individuals and patients with AD. These findings support its further development as a topical selective JAK1 inhibitor for the treatment of atopic dermatitis."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13 • IL22 • IL4

Evaluating the Neuroprotective and Acetylcholinesterase Inhibitory Properties of Four Calcineurin Inhibitor Drugs: Tacrolimus, Pimecrolimus, Cyclosporin A, and Voclosporin. (PubMed, Mol Neurobiol) - "Voc demonstrated superior in vitro AChE inhibition, surpassing galantamine at low concentrations. Moreover, Voc markedly restored cell viability and reduced neuronal degeneration in H2O2-treated cells. These findings suggest CNIs, especially Voc, as promising candidates for ND treatment, targeting AChE overactivity and oxidative stress."

Journal • Alzheimer's Disease • CNS Disorders • Pain • ACHE • CASP3

Adjunctive Use of a Dermocosmetic Regimen in Psoriasis Patients Undergoing Pharmacological Treatment: A 14-Day Clinical Evaluation (ESDR 2025) - "Seventy-five percent were receiving topical corticosteroids (mometasone, betamethasone, clobetasol) or calcineurin inhibitors (tacrolimus, pimecrolimus); the remainder were treated systemically with cyclosporine. Adjunctive skin care with products containing pale ichthyol, chicory root, and willow bark extracts was safe and may enhance treatment outcomes in psoriasis patients. The absence of adverse effects and improvements in skin condition and quality of life suggest these products can support pharmacological therapies effectively."

Clinical • Dermatology • Immunology • Inflammation • Psoriasis

AQUA: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (clinicaltrials.gov) - P3 | N=330 | Recruiting | Sponsor: Sanofi | N=249 ➔ 330

Enrollment change • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Persistent lichen planus pigmentosus inversus in a 45-year-old woman: a decade-long clinical journey and therapeutic challenges in an uncommon dermatological variant. (PubMed, Ann Med Surg (Lond)) - "Treatment with topical steroids, pimecrolimus, tretinoin, and oral prednisolone led to partial resolution, though irritation from pimecrolimus required reduced application. LPPI's clinical course is variable, with treatments like tacrolimus and corticosteroids yielding inconsistent results. This case report documents a rare instance of pigmented inverse lichen planus in a 45-year-old woman, highlighting its chronic nature, treatment resistance, and ongoing challenges in managing pigmentation."

Journal • Dermatology • Dermatopathology • Lichen Planus • Mood Disorders • Pruritus

The Importance of Histopathology in the Diagnosis of Annular Lichenoid Dermatitis of Youth: A Case Report. (PubMed, Case Rep Dermatol) - "A mycological examination was negative, and symptomatic treatment with hydrocortisone and pimecrolimus led to temporary lesion resolution, but recurrence followed treatment cessation. The chronic and recurrent nature of ALDY underscores the importance of long-term management strategies, including topical corticosteroids and immunomodulators. Awareness of ALDY among dermatologists can aid in early recognition and appropriate management, ultimately improving patient outcomes."

Journal • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Dermatopathology • Immunology • Mycosis Fungoides • Oncology • Pediatrics

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013-2023. (PubMed, Diseases) - "In 2022, the FDA approved Ruxolitinib cream, targeting the JAK/STAT pathway for NSV treatment based on promising results. This research conducts a retrospective descriptive safety assessment of Tacrolimus, Pimecrolimus, and Ruxolitinib safety in vitiligo treatment, utilizing the FDA Adverse Event Reporting System (FAERS) database spanning the period from 2013 to 2023 and including patients aged 2 years and above, encompassing both brand and generic names...Local dermatological side effects reported were generally mild, not warranting treatment cessation. In conclusion, vitiligo significantly impacts patients' psychological well-being, necessitating continuous post-marketing safety monitoring for topical medications."

Adverse events • Journal • Review • Cardiovascular • Dermatology • Hematological Disorders • Immunology • Musculoskeletal Diseases • Orthopedics • Pain • Urticaria • Vitiligo

Ex Vivo Modeling and Pharmacological Modulation of Tissue Immune Responses in Inflammatory Bowel Disease Using Precision-Cut Intestinal Slices. (PubMed, Eur J Immunol) - "Pimecrolimus treatment led to a marked reduction in the release of IL-2, IL-17A, and IFN-γ, and inhibited the IBD supernatant-induced reduction in transepithelial electrical resistance. Our data provide the first in-depth characterization of local tissue immune responses in human PCIS, highlighting the potential of this model to study disease-specific immune activity and evaluate pharmacological interventions ex vivo."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immune Modulation • Immunology • Inflammation • Inflammatory Bowel Disease • CXCL5 • IFNG • IL17A • IL21 • IL22

Dupilumab Treatment for Atopic Dermatitis Is Associated With Decreased Risk of Otitis Media and Related Surgical Procedures: A Retrospective Cohort Study. (PubMed, Pediatr Dermatol) - "Overall, reduced risk of OM and related surgical procedures is observed in patients with AD treated with dupilumab compared to those treated with pimecrolimus."

Journal • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Otorhinolaryngology • Pediatrics

Pregnane X Receptor Activation Induces Ferroptosis Resistance Through Upregulation of FSP1. (PubMed, Mol Carcinog) - "Activation of PXR by rifaximin and rifampicin suppresses ferroptosis in a variety of cancer cells from different origins. Importantly, we demonstrated that the PXR inhibitor pimecrolimus showed synergy with ferroptosis inducer sulfasalazine to repress tumor growth in vivo. Together, these findings provide evidence supporting an anti-ferroptosis role of PXR through the upregulation of FSP1 expression."

Journal • Oncology • AIFM2